Description of a Sample of Patients with Chronic Obstructive Pulmonary Disease Treated at Hospital-Supervised Respiratory Clinics at Primary Care Centers;Descripción de una Muestra de Pacientes con Enfermedad Pulmonar Obstructiva Crónica Atendidos en las Consultas del Área de Neumología Dependientes de un Hospital

Archivos de Bronconeumologia

Volumn 39, Issue 11, 2003, Pages 485-490

  Esteban, C ^a   Moraza, J ^a   Aburto, M ^a   Quintana, J M ^a   Capelastegui, A ^a  

^a HOSPITAL DE GALDAKAO   (Spain)

Author keywords

Chronic obstructive pulmonary disease; Descriptive study; Dyspnea

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; STEROID;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; DAILY LIFE ACTIVITY; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH BEHAVIOR; HOSPITAL; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOARTHRITIS; PATIENT ATTITUDE; PRIMARY MEDICAL CARE; SPINE DISEASE; SPIROMETRY;

EID: 0242494225     PISSN: 03002896     EISSN: None     Source Type: Journal    
DOI: 10.1157/13053211     Document Type: Article

References (22)

1. Sobradillo V, Miravitlles M, Jiménez CA, Gabriel R, Viejo JL, Masa JF, et al. Estudio IBERPOC en España: prevalencia de síntomas respiratorios habituales y de limitación crónica al flujo aéreo. Arch Bronconeumol 1999;35:159-66.
2. Pellicer C, Fullana J, Cremades MJ, Rivera ML, Perpiña M. Perfil de una consulta de neumología de ámbito comarcal. Arch Bronconeumol 1996;32:447-52.
3. Hurd S. The impact of COPD on lung health worlwide. Epidemiology and incidence. Chest 2000;117:1S-4S.
4. Celli BR. Monitoring the progression of chronic obstructive pulmonary disease: a time for a new staging system. Eur Respir Rev 1999;9:165-8.
5. Fletcher CM, Elmes PC, Wood CH. The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population. BMJ 1959;2:257-66.
6. Sanchis J. Normativa para la espirometría forzada. Grupo de trabajo de la SEPAR para la práctica de la espirometría clínica. Arch Bronconeumol 1989;25:132-42.
7. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report working party standardization of lung function test, European Community for Steel and Coal. Official statement of the European Respiratory Society. Eur Respir J 1993;16:5-40.
8. Barberá JA, Peces-Barba G, Agustí AGN, Izquierdo JL, Monsó E, Montemayor T, et al. Guía clínica para el diagnóstico y tratamiento de la enfermedad pulmonar obstructiva crónica. Arch Bronconeumol 2001;37:297-316.
9. Skwarska E, Cohen G, Skwarski C, Lamb C, Bushell D, Parker S, et al. Randomised controlled trial of supported discharge in patients with exacerbations of chronic obstructive pulmonary disease. Thorax 2000;55:907-12.
10. Ruigómez A, Alonso J, Antó JM. Salud percibida y capacidad funcional de la población anciana no institucionalizada de Barcelona. Gacet Sanit 1991;5:117-24.
11. Black LF, Mitchell MM. Evaluation of a patient education program for chronic obstructive pulmonary disease. Mayo Clin Proc 1977;52:106-11.
12. Lores Obradors L, Monsó Molás E, Rosell Gratacós A, Badorrey Y, Sampablo Lauro Y. ¿ Nos mienten los enfermos controlados en un dispensario de neumología respecto a su hábito tabáquico? Arch Bronconeumol 1999;35:219-22.
13. Pauwels RA, Buist AS, Calverley PMA, Jenkins CR, Hurd SS, on behalf of the GOLD Scientific Committee. Global Strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop Summary. Am J Respir Crit Care Med 2001;163:1256-76.
14. Burge PS, Calverley PMA, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320:1297-303.
15. Lung Health Study. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000;343:1902-9.
16. Sin DD, Tu JV. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronicobstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:580-4.
17. Ferrer M, Alonso J, Morera J, Marrades RM, Khalaf A, Aguar C, et al. Chronic obstructive pulmonary disease stage and health-related quality of life. Ann Intern Med 1997;127:1072-9.
18. Yohannes AM, Baldwin RC, Connolly MS. Depression and anxiety in elderly outpatients with chronic obstructive pulmonary disease: prevalence and validationof the BASDEC scrrening questionnaire. J Geriatr Psychiatry 2000;15:1090-6.
19. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dysnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999;54:581-6.
20. Engström CP, Persson LO, Larsson S, Rydén A, Sullivan M. Functional status and well being in chronic obstructive pulmonary disease with regard to clinical parameters and smoking: a descriptive and comparative study. Thorax 1996;51:825-30.
21. Garrod R, Bestall JC, Paul EA, Wedzicha JA, Jones PW. Development and validation of a standardized measure of activity of daily living in patients with severe COPD: the London Chest Activity Of Daily Living scale (LCADL). Respir Med 2000;94:589-96.
22. Monsó E, Fiz JM, Izquierdo J, Alonso J, Coll R, Rosell A, et al. Quality of life in severe chronic obstructive pulmonary disease: correlation with lung and muscle function. Respir Med 1998;92:221-7.